Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 30,058
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12540187 | Method of treating vascular eye and retinal diseases by administration of anti-Neuropilin 1A antibodies | 🖼🧊📄§ | 2026-02-03 | 2043-04-07 | 0 | 31 |
| 12539326 | Methods for treating Alzheimer's disease using semaglutide | 🖼🧊📄§ | 2026-02-03 | 2044-12-12 | 0 | 31 |
| 12540192 | CD20 binding single domain antibodies | 🖼🧊📄§ | 2026-02-03 | 2041-12-21 | 0 | 31 |
| 12539313 | Microbial removal | 🖼🧊📄§ | 2026-02-03 | 2040-03-03 | 0 | 31 |
| 12540189 | Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein | 🖼🧊📄§ | 2026-02-03 | 2043-03-08 | 0 | 31 |
| 12540166 | BNIP3 peptides for treatment of reperfusion injury | 🖼🧊📄§ | 2026-02-03 | 2040-05-08 | 0 | 31 |
| 12540149 | Aromatic heterocyclic compound, pharmaceutical composition, and use thereof | 🖼🧊📄§ | 2026-02-03 | 2041-08-27 | 0 | 31 |
| 12540157 | Oxysterols and methods of use thereof | 🖼🧊📄§ | 2026-02-03 | 2043-11-09 | 0 | 31 |
| 12540191 | Engineered immune cells targeting BCMA and their uses thereof | 🖼🧊📄§ | 2026-02-03 | 2043-09-29 | 0 | 31 |
| 12540141 | Spiropyrrolidine derived antiviral agents | 🖼🧊📄§ | 2026-02-03 | 2041-11-22 | 0 | 31 |
| 12540197 | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates | 🖼🧊📄§ | 2026-02-03 | 2044-10-11 | 0 | 31 |
| 12539310 | Hetero-structured ribonucleic acid and use thereof | 🖼🧊📄§ | 2026-02-03 | 2041-10-26 | 0 | 31 |
| 12540167 | Cytokine combination | 🖼🧊📄§ | 2026-02-03 | 2042-11-17 | 0 | 31 |
| 12539305 | Methods of treating cancer with an mTOR inhibitor | 🖼🧊📄§ | 2026-02-03 | 2043-05-25 | 0 | 31 |
| 12539297 | Composition for inhibiting cancer metastasis and treating cancer | 🖼🧊📄§ | 2026-02-03 | 2042-05-11 | 0 | 31 |
| 12539278 | Nanocomposite particle and uses thereof | 🖼🧊📄§ | 2026-02-03 | 2040-09-01 | 0 | 31 |
| 12539327 | Norovirus S particle based vaccines and methods of making and using same | 🖼🧊📄§ | 2026-02-03 | 2043-10-19 | 0 | 31 |
| 12540143 | Methods and compositions for targeted protein degradation | 🖼🧊📄§ | 2026-02-03 | 2040-04-08 | 0 | 31 |
| 12539340 | Radioconjugates targeting CD33 in the treatment of cancers | 🖼🧊📄§ | 2026-02-03 | 2042-08-08 | 0 | 31 |
| 12539298 | Lobinaline N-oxides as positive allosteric modulators of the dopamine transporter with potential value in the treatment of substance abuse disorders | 🖼🧊📄§ | 2026-02-03 | 2040-11-25 | 0 | 31 |
| 12540136 | Pyrrolopyridine derivative and use thereof | 🖼🧊📄§ | 2026-02-03 | 2041-08-20 | 0 | 31 |
| 12540137 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | 🖼🧊📄§ | 2026-02-03 | 2044-05-16 | 0 | 31 |
| 12539323 | Anti-psychotic composition and treatment methods | 🖼🧊📄§ | 2026-02-03 | 2041-12-01 | 0 | 31 |
| 12540190 | Anti-BCMA antibody, antigen-binding fragment thereof and medical use thereof | 🖼🧊📄§ | 2026-02-03 | 2040-07-29 | 0 | 31 |
| 12540184 | Association of polyclonal antibodies and anti-PD1 or anti-PDL1 antibodies for the treatment of cancer | 🖼🧊📄§ | 2026-02-03 | 2040-04-28 | 0 | 31 |
| 12540334 | Gene therapy for Alzheimer's disease | 🖼🧊📄§ | 2026-02-03 | 2040-05-21 | 0 | 31 |
| 12539317 | Gene expression system for probiotic microorganisms | 🖼🧊📄§ | 2026-02-03 | 2044-03-26 | 0 | 31 |
| 12539320 | Composition for improving eyesight | 🖼🧊📄§ | 2026-02-03 | 2043-04-13 | 0 | 31 |
| 12540335 | Compositions and methods for the treatment of metabolic liver disorders | 🖼🧊📄§ | 2026-02-03 | 2041-03-04 | 0 | 31 |
| 12539271 | Nanoparticulate compositions | 🖼🧊📄§ | 2026-02-03 | 2042-04-14 | 0 | 31 |
| 12539316 | Compositions and methods for stem cell transplant | 🖼🧊📄§ | 2026-02-03 | 2039-04-11 | 0 | 31 |
| 12539319 | Lactobacillus delbrueckii subsp. lactis CKDB001 strain, and composition for prevention, amelioration, or treatment of non-alcoholic fatty liver comprising same | 🖼🧊📄§ | 2026-02-03 | 2041-03-23 | 0 | 31 |
| 12540175 | Anti-ApoE antibodies | 🖼🧊📄§ | 2026-02-03 | 2044-02-08 | 0 | 31 |
| 12540185 | Fabs-in-tandem immunoglobulin and uses thereof | 🖼🧊📄§ | 2026-02-03 | 2042-07-12 | 0 | 31 |
| 12540181 | Anti-CD19/anti-CD3 bispecific antibody, T cells secreting the same, method of preparation and use thereof | 🖼🧊📄§ | 2026-02-03 | 2041-02-16 | 0 | 31 |
| 12540133 | Potent and selective compounds as serotonin 1B receptor modulators | 🖼🧊📄§ | 2026-02-03 | 2041-10-07 | 0 | 31 |
| 12540372 | Titania based generators for AC-225 generation | 🖼🧊📄§ | 2026-02-03 | 2042-04-20 | 0 | 31 |
| 12540186 | Anti-EGFRvIII antibodies and antigen-binding fragments thereof | 🖼🧊📄§ | 2026-02-03 | 2040-03-23 | 0 | 31 |
| 12540174 | Kits and containers for treating vimentin expressing tumors | 🖼🧊📄§ | 2026-02-03 | 2042-10-07 | 0 | 31 |
| 12539329 | Treatment regimen for the treatment of autoimmune disorders | 🖼🧊📄§ | 2026-02-03 | 2044-03-08 | 0 | 31 |
| 12533389 | Glycopeptide antibiotic combination therapy | 🖼🧊📄§ | 2026-01-27 | 2042-07-26 | 0 | 31 |
| 12534471 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | 🖼🧊📄§ | 2026-01-27 | 2044-04-08 | 0 | 31 |
| 12533421 | Methods for making multilayered vesicles | 🖼🧊📄§ | 2026-01-27 | 2042-02-16 | 0 | 31 |
| 12534465 | 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof | 🖼🧊📄§ | 2026-01-27 | 2040-06-10 | 0 | 31 |
| 12533337 | Pharmaceutical drug containing heterocyclidene acetamide derivative | 🖼🧊📄§ | 2026-01-27 | 2040-10-02 | 0 | 31 |
| 12533348 | Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (TDT) | 🖼🧊📄§ | 2026-01-27 | 2040-07-17 | 0 | 31 |
| 12534440 | Compounds with copper- or zinc-activated toxicity against microbial infection | 🖼🧊📄§ | 2026-01-27 | 2039-09-20 | 0 | 31 |
| 12534470 | DNA polymerase IIIC inhibitors and use thereof | 🖼🧊📄§ | 2026-01-27 | 2043-04-11 | 0 | 31 |
| 12534741 | Compositions and methods for treatment of neurological disorders | 🖼🧊📄§ | 2026-01-27 | 2043-07-19 | 0 | 31 |
| 12534726 | Composition and method for inhibiting angiotensinogen (AGT) protein expression | 🖼🧊📄§ | 2026-01-27 | 2045-03-19 | 0 | 31 |